Literature DB >> 23372034

JAK inhibitors: beyond spleen and symptoms?

Francisco Cervantes, Ruben Mesa, Claire Harrison.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23372034      PMCID： PMC3561420          DOI： 10.3324/haematol.2012.083543

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  Long-term outcome of treatment with ruxolitinib in myelofibrosis.

Authors:  Ayalew Tefferi; Mark R Litzow; Animesh Pardanani
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

2.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.

Authors:  Srdan Verstovsek; Hagop M Kantarjian; Zeev Estrov; Jorge E Cortes; Deborah A Thomas; Tapan Kadia; Sherry Pierce; Elias Jabbour; Gautham Borthakur; Elisa Rumi; Ester Pungolino; Enrica Morra; Domenica Caramazza; Mario Cazzola; Francesco Passamonti
Journal:  Blood       Date:  2012-06-20       Impact factor: 22.113

5.  Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Authors:  Animesh Pardanani; Jason R Gotlib; Catriona Jamieson; Jorge E Cortes; Moshe Talpaz; Richard M Stone; Michael H Silverman; D Gary Gilliland; Jolene Shorr; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544
  5 in total
  6 in total

Review 1.  The role of JAK inhibitors in hematopoietic cell transplantation.

Authors:  Rachel B Salit
Journal:  Bone Marrow Transplant       Date:  2022-04-06       Impact factor: 5.174

Review 2.  Ruxolitinib for myelofibrosis--an update of its clinical effects.

Authors:  Hagop M Kantarjian; Richard T Silver; Rami S Komrokji; Ruben A Mesa; Roland Tacke; Claire N Harrison
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-10-02

Review 3.  Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors:  Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

Review 4.  Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.

Authors:  A Yacoub; O Odenike; S Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 5.  Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.

Authors:  Jeffrey C Bryan; Srdan Verstovsek
Journal:  Cancer Chemother Pharmacol       Date:  2016-03-26       Impact factor: 3.333

Review 6.  JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.

Authors:  Karoline Gäbler; Iris Behrmann; Claude Haan
Journal:  JAKSTAT       Date:  2013-05-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.